JoseMiguelTrevejoMD

Infectious Disease • Boston, MA

Physician

Join to view full profile

Dr. Trevejo is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Trevejo's full profile

Already have an account?

Office
110 Francis St
Ste Gb
Boston, MA 02215
Phone+1 617-632-7706

Education & Training

Beth Israel Deaconess Medical CenterFellowship, Infectious Disease, 2004 - 2008
Brigham and Women's HospitalResidency, Internal Medicine, 2002 - 2005
Weill Cornell MedicineClass of 2002

Certifications & Licensure

MA State Medical License 2004 - 2026

Clinical Trials

A Study to Investigate VX-787 Given to Adult Volunteers Inoculated With Live Influenza Virus Start of enrollment: 2012 Mar 01
Completed
Phase 2

Publications & Presentations

PubMed

83 citations
Implications of antibody-dependent enhancement of infection for SARS-CoV-2 countermeasures.
Nikolai Eroshenko, Taylor Gill, Marianna K Keaveney, George M. Church, Jose M Trevejo
Nature Biotechnology. 2020-07-01
58 citations
Safety and efficacy of monoclonal antibody VIS410 in adults with uncomplicated influenza A infection: Results from a randomized, double-blind, phase-2, placebo-control...
Ellie Hershberger, Susan Sloan, Kristin Narayan, Catherine A. Hay, Patrick F. Smith
Ebiomedicine. 2019-02-01
41 citations
Pimodivir treatment in adult volunteers experimentally inoculated with live influenza virus: a Phase IIa, randomized, double-blind, placebo-controlled study.
Jose M Trevejo, Mohammed Asmal, Johan Vingerhoets, Ramon Polo, Sarah Robertson
Antiviral Therapy. 2017-05-01

Press Mentions

Rocket Pharmaceuticals Reports First Quarter 2021 Financial Results and Highlights Recent ProgressMay 10th, 2021
Sorrento Enters into Merger Agreement to Acquire SmartPharm and Develop Pipeline of Gene-Encoded Therapeutic Antibodies, Starting with Neutralizing Antibodies to Treat COVID-19 and Cancer TherapeuticsAugust 20th, 2020
Visterra Announces Publication of Clinical Data on VIS410 in the Journal EBioMedicineFebruary 26th, 2016